LLYEli Lilly

Health care · Pharmaceuticals · NYSE

Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. 10-K, Item 1

Employees: 50,000
Headquarters: Indianapolis, IN
CEO: David A. Ricks
Next results: around Feb 3, 2027

Compare with peers → Embed

The numbers LLY said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.

Of 4 range targets with a reported result: 2 came in above the last range given, 0 within it, 2 below it.

Target	What the company said	Reported	Result
Diluted EPS (company-defined) Fiscal 2026	Given $33.50 to $35.00 release 2026-02-04 Raised $35.50 to $37.00 release 2026-04-30	–	No standard number
The company's words 2026 guidance issued with revenue in the range of $80 billion to $83 billion and non-GAAP EPS in the range of $33.50 to $35.00. release 2026-02-04 Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00. release 2026-04-30
Revenue Fiscal 2026	Given $80.00B to $83.00B release 2026-02-04 Raised $82.00B to $85.00B release 2026-04-30	–	Not reported yet
The company's words 2026 guidance issued with revenue in the range of $80 billion to $83 billion and non-GAAP EPS in the range of $33.50 to $35.00. release 2026-02-04 Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00. release 2026-04-30
Diluted EPS Fiscal 2025 (ended 2025-12-31)	Given $22.05 to $23.55 release 2025-02-06 Lowered $20.17 to $21.67 release 2025-05-01 Raised $20.85 to $22.10 release 2025-08-07 Raised $21.80 to $22.50 release 2025-10-30	$22.95 10-K filed 2026-02-12	Above the range
The company's words 2025 guidance issued with revenue in the range of $58.0 billion to $61.0 billion, EPS in the range of $22.05 to $23.55 and non-GAAP EPS in the range of $22.50 to $24.00. release 2025-02-06 Guidance … Earnings per share (reported) $20.17 to $21.67 release 2025-05-01 Increased the midpoint of our 2025 full-year revenue guidance by $1.5B to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00 release 2025-08-07 Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. release 2025-10-30
Diluted EPS (company-defined) Fiscal 2025 (ended 2025-12-31)	Given $22.50 to $24.00 release 2025-02-06 Lowered $20.78 to $22.28 release 2025-05-01 Raised $21.75 to $23.00 release 2025-08-07 Raised $23.00 to $23.70 release 2025-10-30	–	No standard number
The company's words 2025 guidance issued with revenue in the range of $58.0 billion to $61.0 billion, EPS in the range of $22.05 to $23.55 and non-GAAP EPS in the range of $22.50 to $24.00. release 2025-02-06 Guidance … Earnings per share (non-GAAP) $20.78 to $22.28 release 2025-05-01 Increased the midpoint of our 2025 full-year revenue guidance by $1.5B to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00 release 2025-08-07 Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. release 2025-10-30
Revenue Fiscal 2025 (ended 2025-12-31)	Given $58.00B to $61.00B release 2025-01-14 Kept $58.00B to $61.00B release 2025-02-06 Kept $58.00B to $61.00B release 2025-05-01 Raised $63.00B to $63.50B release 2025-10-30	$65.18B 10-K filed 2026-02-12	Above the range
The company's words The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue INDIANAPOLIS, January 14, 2025 -- Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year. release 2025-01-14 2025 guidance issued with revenue in the range of $58.0 billion to $61.0 billion, EPS in the range of $22.05 to $23.55 and non-GAAP EPS in the range of $22.50 to $24.00. release 2025-02-06 The company reaffirms its previous 2025 revenue guidance and expects it to be between $58.0 billion and $61.0 billion. release 2025-05-01 Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. release 2025-10-30
Diluted EPS Fiscal 2024 (ended 2024-12-31)	Given $11.80 to $12.30 release 2024-02-06 Raised $13.05 to $13.55 release 2024-04-30 Raised $15.10 to $15.60 release 2024-08-08	$11.71 10-K filed 2025-02-19	Below the range
The company's words 2024 guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70. release 2024-02-06 2024 full-year revenue guidance raised by $2.0 billion; reported EPS guidance raised $1.25 to be in the range of $13.05 to $13.55 and non-GAAP EPS guidance raised $1.30 to be in the range of $13.50 to $14.00. release 2024-04-30 2024 full-year revenue guidance raised by $3 billion; reported EPS guidance raised $2.05 to the range of $15.10 to $15.60, and non-GAAP EPS guidance raised $2.60 to the range of $16.10 to $16.60. release 2024-08-08
Diluted EPS (company-defined) Fiscal 2024 (ended 2024-12-31)	Given $12.20 to $12.70 release 2024-02-06 Raised $13.50 to $14.00 release 2024-04-30 Raised $16.10 to $16.60 release 2024-08-08 Lowered $13.02 to $13.52 release 2024-10-30	–	No standard number
The company's words 2024 guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70. release 2024-02-06 2024 full-year revenue guidance raised by $2.0 billion; reported EPS guidance raised $1.25 to be in the range of $13.05 to $13.55 and non-GAAP EPS guidance raised $1.30 to be in the range of $13.50 to $14.00. release 2024-04-30 2024 full-year revenue guidance raised by $3 billion; reported EPS guidance raised $2.05 to the range of $15.10 to $15.60, and non-GAAP EPS guidance raised $2.60 to the range of $16.10 to $16.60. release 2024-08-08 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges incurred in Q3. release 2024-10-30
Revenue Fiscal 2024 (ended 2024-12-31)	Given $40.40B to $41.60B release 2024-02-06 Raised $45.40B to $46.00B release 2024-10-30	$45.04B 10-K filed 2025-02-19	Below the range
The company's words 2024 guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70. release 2024-02-06 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges incurred in Q3. release 2024-10-30

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (14 releases since 2023-11-02), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Work on LLY in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/LLY/export.csv") into a cell.